Andrea Mengarelli

Prof. Andrea Mengarelli

IRCCS REGINA ELENA NATIONAL CANCER INSTITUTE, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1998 in Neurology
Verified
Journal Article
Closed access
PDF file
GAG. Antonini
G. Antonini
VCV. Ceschin
V. Ceschin
SMS. Morino
S. Morino
MFMarco Fiorelli
Marco Fiorelli
FGF. Gragnani
F. Gragnani
william arcesewilliam arcese
william arcese
Background: Bone marrow transplant (BMT) is used for both neoplastic and nonneoplastic diseases. Following BMT, particularly during the first 3 months, patients have a number of neurologic complications. We evaluated the early neurologic complications following BMT and their influence on survival. Methods: We prospectively followed 115 consecutive patients having BMT for leukemia, for a median period of 90 days after transplantation. Results: Sixty-four patients (56%) had neurologic complications. Sixteen developed more than one complication. Twenty-seven patients (25%) had major neurologic complications: metabolic encephalopathy (8), seizures (8), psychiatric symptoms (3), cerebral hemorrhage (1), cerebral abscess (1), leukemic meningitis (1), peripheral neuropathies (5), and myopathies (2). Forty patients (35%) had minor complications, including headache (16) and tremor(31). Major neurologic complications occurred after engraftment in most patients. Metabolic encephalopathy correlated with graft-versus-host disease(GVHD) (p < 0.03). Seven percent of patients had generalized seizures that occurred without signs of structural cerebral lesions. Probability of survival at day 90 was lower in patients with than in those without major central nervous system complications (63% versus 87.5%, p < 0.01). Conclusions: Neurologic complications are frequent during the first 3 months following BMT and affect patient survival. Drug neurotoxicity and acute GVHD are the main factors influencing their occurrence.

29 June 2017 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
FMFrancesco Marchesi
Francesco Marchesi
FPF. Pimpinelli
F. Pimpinelli
FEF. Ensoli
F. Ensoli
AMAndrea Mengarelli
Andrea Mengarelli

12 January 2018 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
JOJacopo Olivieri
Jacopo Olivieri
IAImmacolata Attolico
Immacolata Attolico
RNRoberta Nuccorini
Roberta Nuccorini
SPSara Pasquina Pascale
Sara Pasquina Pascale
MCMartina Chiarucci
Martina Chiarucci
AOAttilio Olivieri
Attilio Olivieri

1 July 2013 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
FMFrancesco Marchesi
Francesco Marchesi
NCNatalia Cenfra
Natalia Cenfra
LALidia Altomare
Lidia Altomare
MDMaria L. Dessanti
Maria L. Dessanti
SMSergio Mecarocci
Sergio Mecarocci
GCGuiseppe Cimino
Guiseppe Cimino

12 November 2013 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
FMFrancesco Marchesi
Francesco Marchesi
AMAndrea Mengarelli
Andrea Mengarelli
FGF. Giannotti
F. Giannotti
ATA. Tendas
A. Tendas
BAB. Anaclerico
B. Anaclerico
TNThe Rome Transplant Network
The Rome Transplant Network

27 September 2003 in Leukemia
Verified
Journal Article
Closed access
PDF file
FLF Lo-Coco
F Lo-Coco
ARA Romano
A Romano
AMAndrea Mengarelli
Andrea Mengarelli
DDD Diverio
D Diverio
AIA P Iori
A P Iori
william arcesewilliam arcese
william arcese